Scilex Holding Co Warrant (SCLXW)

• Market cap: $1.28M
• 1 day: -16.23%
• 5 days: -19.17%
• 1 month: -44.44%
• 3 months: -34.37%
• 6 months: -28.04%
• Year to date: -11.98%
• 1 year: -75.75%
• 5 years: -80.92%
• 10 years: -83.33%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

Employees: 34